3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Polycystic Ovary Syndrome
13
Obesity
6
Weight Loss
5
Overweight
3
Menstruation Disturbances
2
Intermittent Fasting
2
Insulin Resistance
2
Tumor Surgery
1
Sarcopenia
1
Postoperative Complications
1
Obesity, Abdominal
1
Muscle Weakness
1
Motor Activity
1
Moderately Overweight Individuals
1
Metabolic Syndrome
1
Metabolic Diseases
1
Infertility
1
Glucocorticoid Receptor Deficiency
1
Fasting
1
Esophageal Neoplasms
1
Colorectal Neoplasms
1
Breast Neoplasms
1
Breast Cancer Female
1
Body Weight
1
Interventions
Cisplatin
160
Fluorouracil
134
Paclitaxel
125
Radiotherapy
117
Oxaliplatin
87
Docetaxel
70
Carboplatin
70
Irinotecan
59
pembrolizumab
57
Capecitabine
57
Leucovorin
56
Radiation
47
Surgical Procedures, Operative
33
Drug Therapy
33
Esophagectomy
31
Cetuximab
25
Neoadjuvant Therapy
24
Nivolumab
23
Bevacizumab
21
Trastuzumab
20
camrelizumab
19
S 1 (combination)
19
Chemoradiotherapy
17
Albumin-Bound Paclitaxel
16
Magnetic Resonance Spectroscopy
15
Epirubicin
15
tislelizumab
14
Taxes
13
Radiotherapy, Intensity-Modulated
13
Cyclophosphamide
13
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Esophageal Neoplasms
×
Caloric Restriction
×
Clear all
NCT03676478
2025-12-10
EFECTS
University Hospital, Gasthuisberg
Phase NA
Terminated
239 enrolled